Objectives: Economic evaluations of interventions to prevent and control sexually transmitted infections such as Chlamydia trachomatis are increasingly required to present their outcomes in terms of quality-adjusted life-years using preference-based measurements of relevant health states. The objectives of this study were to critically evaluate how published cost-effectiveness studies have conceptualized and valued health states associated with chlamydia and to examine the primary evidence available to inform health state utility values (HSUVs). Methods: A systematic review was conducted, with searches of six electronic databases up to December 2012. Data on study characteristics, methods, and main results were extracted by using a standard template. Results: Nineteen economic evaluations of relevant interventions were included. Individual studies considered different health states and assigned different values and durations. Eleven studies cited the same source for HSUVs. Only five primary studies valued relevant health states. The methods and viewpoints adopted varied, and different values for health states were generated.
Introduction
Evidence about the cost-effectiveness of health care interventions is an integral requirement for key decision-making bodies in many countries, including the United Kingdom [1, 2] . Many decision-making bodies require interventions to be assessed in terms of their cost per quality-adjusted life-year (QALY), which combines improvements in health-related quality of life (HRQOL) and life expectancy with people's relative preferences for health states [3] . Preference-based health state utility values (HSUVs) assign a value to the health states experienced by the patient. A value of "1" represents full health, and a value of "0" indicates a health state equivalent to being dead. Utility values can be generated directly or indirectly. Standard gamble or time tradeoff (TTO) techniques generate direct valuations from patients or the public on the basis of their experiences or hypothetical scenarios. Indirect methods typically use an instrument to measure HRQOL and then apply preference values obtained from surveys of the general public [4] . The conceptualization of health states and the application of HSUVs can have a major effect on results of cost-effectiveness studies [5, 6] . There is a growing body of literature with estimates for HSUVs for a wide range of conditions that can be used to inform cost-effectiveness studies when reliance on primary data is not possible or valid [7] . There are many disease areas, however, in which HSUVs are less widely available, and there are subsets of populations for whom preference-based measurements of HRQOL are less well researched or in whom such measurement is perceived as more difficult [8, 9] .
Cost-effectiveness studies influence decisions about funding for particular interventions, and so their methodological quality is extremely important [10] . While there has been a growing literature aimed at improving the standard of economic
The Challenges Associated with Valuing Health States for Chlamydia
We believe that there are several challenges to the identification, assessment, and utilization of appropriate information on HSUVs for use in economic evaluations of STIs such as chlamydia. First, there are considerations relating to the actual state of infection itself. Chlamydia, like many STIs, is often asymptomatic, and so most infected individuals do not experience any apparent detriment to their quality of life at the time of infection [34] , even though the average duration of untreated infection is more than 1 year and people are infectious throughout [26] . There is qualitative evidence, however, to suggest that being tested for chlamydia and receiving a positive diagnosis does have an impact on quality of life, particularly for women [35, 36] . Second, owing to the obvious ethical and practical issues associated with studying untreated chlamydia, there is considerable uncertainty about the natural history of infection and disease, including the timing, incidence, and duration of complications [37, 38] and rates and risks associated with reinfection [31] .
Third, chlamydia is only one cause of many of the late sequelae associated with the infection. There is limited evidence about whether the etiology of conditions such as chronic pelvic pain or infertility affects HRQOL [39] [40] [41] . Qualitative evidence suggests that the stigma associated with STIs mediates the experience of being in the health state [35] , and so HRQOL might differ between women with infertility secondary to an STI and those with cancer, for example. Fourth, the health states associated with chlamydial disease last for different amounts of time; tubal infertility might be permanent, while the infection itself and some of its sequelae, such as PID and ectopic pregnancy, are temporary states [42, 43] . Temporary health states might involve different methods for valuation, and there is a need to consider how preferences for temporary and permanent states are combined [44] . Fifth, the sequelae associated with chlamydia sometimes occur many years after the initial infection [37] , and so issues of time preference are likely to have an effect on the valuation of the health states [45, 46] . Finally, the burdens associated with the disease are asymmetrical; although both men and women experience infection, the main complications associated with chlamydia affect women of reproductive age [31] , but fertility problems can affect others besides the woman herself. This might affect the conceptualization of health outcomes and decisions about whose preferences should count [47, 48] .
The objectives of this study were to identify and critically evaluate economic evaluations that included QALYs as an outcome measure to identify how health states have been conceptualized and valued within cost-effectiveness studies. Primary studies that valued relevant health states were also located to examine the data that could be used to inform cost-effectiveness studies incorporating HSUVs for chlamydia and its sequelae.
Methods
We conducted a systematic review following UK Centre for Review and Dissemination guidelines for methods and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting, where appropriate [49, 50] .
Inclusion Criteria
Articles were included if they met the following criteria: the participants were men or women with, or at risk of, sexually transmitted chlamydia or its sequelae; the intervention (for economic evaluations) was any medical procedure to prevent, control, or treat chlamydia infection or its sequelae; the main outcomes were either cost per QALY (for economic evaluations) or the measurement and valuation of health states associated with chlamydial infection and its sequelae. We excluded articles that were wholly concerned with conditions affecting the pelvic area and not likely to be connected with STIs.
Search Strategy
The search strategy was constructed to be as inclusive as possible. Six electronic databases were searched (EMBASE, MEDLINE, ISI Web of Science, NHS Economic Evaluation Database, Database of Abstracts of Reviews of Effects, and Health Technology Assessment) up to December 2012 (see Appendix 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2013.10.007). The reference lists of potentially relevant articles were then manually searched to identify additional studies. We used a three-stage process to identify studies for inclusion, using methods that have been described in detail elsewhere [51] . Two reviewers initially screened articles by using the title and abstract to classify them into five groups (A-E) (see Appendix 2 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2013.10.007). Second, two reviewers read the full texts of potentially relevant studies and further classified them (see Appendix 2) . Quality assessment criteria were not applied to exclude studies because so few were identified. For each included study, one reviewer extracted data about the study characteristics, the characteristics of the partic ipants, the health states examined, the methods and instrument (s) used, and the results reported and a second reviewer checked the data. The data were tabulated, and the findings of individual studies were compared narratively.
Results
The electronic database search identified 6383 published articles, of which 2001 were duplicates. Figure 1 shows a flow diagram of the articles identified, retrieved, and retained or excluded at each stage and the categorization of the articles.
Nineteen economic evaluations using QALYs were identified, and all were included for data extraction. There were 58 articles that incorporated descriptive measurement of HRQOL for chlamydia and associated conditions but only 5 that included preference-based measurement of such health states. Table 1 summarizes the characteristics of the 19 studies. Four studies included individuals who were considered to be at high risk of STIs [52] [53] [54] [55] . Ten articles examined interventions to provide chlamydia or gonorrhea screening [52] [53] [54] [56] [57] [58] [59] [60] [61] [62] , while two articles examined different aspects of interventions to treat or prevent PID [63, 64] . Two studies focused on behavioral interventions [55, 65] , and one study examined a multifaceted intervention to provide information and increased availability of testing and treatment [66] . One article was concerned with the overall costs and "burden of disease" for chlamydia in a particular country [67] , and another article aimed to estimate the lifetime cost of PID [68] . Two studies examined the effect of expedited treatment for sexual partners of people with an STI and the effect of contraceptive use on STI prevention [69, 70] . Fifteen studies presented their results in terms of natural units, for example, cost per adverse outcome avoided, as well as cost per QALY.
Economic Evaluations Using Cost Per QALY
Authors of five studies applied HSUVs for uncomplicated chlamydia infection, including cervicitis and urethritis [52, 54, 60, 61, 66] . Most applied HSUVs for one or more named female reproductive tract complications: PID [52, 54, 56, [59] [60] [61] [62] [63] [64] [65] [66] [67] 69, 70] , ectopic pregnancy [54, 56, 57, [59] [60] [61] [62] [63] [64] [65] [66] 70] , tubal factor infertility [54, 56, 57, [59] [60] [61] [62] [63] [64] [65] [66] 68] , and chronic pelvic pain [52, 54, 60, 61, 66] . Fewer studies considered male complications [54, 56, 59, [65] [66] [67] or neonatal complications [56, 59, 66] . Just over half of the studies used HSUVs provided by a study by the Institute of Medicine in the United States [52, [56] [57] [58] [60] [61] [62] [63] [64] 66, 68] although some did not cite the study directly. Of the remaining evaluations, two studies [59, 69] used values elicited from women with PID from the work of Smith et al. [71] and one study used the same source but used values elicited from women without PID [67] . For one costeffectiveness study, the source of the utility values was unclear [55] , and the authors of one economic evaluation used a convenience sample to generate their own utility values [70] .
Although the economic evaluations identified largely relied on the same source for HSUVs, there were differences in the actual values used, the duration over which they were applied, and around the assumed timing and incidence of sequelae ( Table 2 ). The base-case values used for chronic pelvic pain varied between 0.6 [57, [60] [61] [62] [63] [64] 66, 68] and 0.79 [67] and were applied for durations ranging from 5 years [54, [60] [61] [62] 65] to the rest of the woman's life [67] . For ectopic pregnancy, the values adopted varied between 0.58 [60] [61] [62] [63] [64] 66 ] and 1 [57] . For infertility, the utilities included varied between 0.76 [65] and 0.87 [59] . Most analyzed the uncertainty associated with such values in sensitivity analyses [52, [54] [55] [56] [57] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] , and some found that this had an impact on the results of the cost-effectiveness analysis [63, 65, 68] , although factors such as complication and transmission rates were more important. The majority of the studies did not provide information about the utility values they adopted (other than the source), and very few discussed their appropriateness for the population under study. About half of the studies acknowledged the lack of information regarding HSUVs, for example, in relation to the limitations associated with their study [56, [59] [60] [61] [62] 65, 67, 68, 70] (Table 1) .
Primary Studies Providing HSUVs for Relevant Health States
Five primary studies valued HRQOL for health states relevant to chlamydia. Their aims and characteristics are shown in Table 3 ; all were based in the United States. The studies provided valuations for a range of relevant health states including PID, chronic pelvic pain, ectopic pregnancy, and tubal factor infertility.
Pelvic inflammatory disease
Three studies generated utility values for PID [71] [72] [73] . The values obtained for PID treatment (Table 4 ) are difficult to compare between studies because each study made different assumptions about treatment pathways (e.g., inpatient and outpatient care). Two of these measured both public and patient preferences. Smith et al. [71] included valuations from women with a history of PID and women with no experience of this condition. Trent et al. [72] compared the utilities for health states obtained directly from adolescents (assumed to give an indication of the views of patients) and their parents (assumed to represent the views of the public). One study provided preferences from the perspective of the public using indirect methods. The study conducted by the US Institute of Medicine used experts to measure HRQOL using the Health Utilities Index Mark 2 (HUI-2) and then used the tariffs associated with this instrument for valuation, which are based on surveys of the general population [73] . Smith et al. [71] used visual analogue scale and TTO techniques with a 10-year time horizon to value all health states directly, and Trent et al. [72] used visual analogue scale and TTO techniques with a 50-year time horizon. The health states in the US Institute of Medicine study were not described in full, but different time horizons were used for different conditions [73] .
Ectopic pregnancy
Utility values for ectopic pregnancy were generated in three studies [71] [72] [73] by using the methods and participants described earlier. As for PID, the utility values (Table 4 ) could not be directly compared between studies because of differing assumptions made about treatment pathways. The highest utility value for this condition was generated by parents of adolescents for a scenario involving a 15-year-old girl experiencing pain and possibly requiring an operation with the condition resolved in a few weeks (0.9) [72] . The lowest value was generated for inpatient treatment for ectopic pregnancy by using the HUI-2 (0.23, with an expected duration of 3 days), which was followed by outpatient treatment (0.66 for 4 weeks) [73] .
Tubal factor infertility
Four of the primary studies provided utility vales for tubal factor infertility. Two studies used similar scenarios to generate values directly, but with different participants and time horizons. Smith et al. [71] reported lower utility values for women with experience of PID (0.76) than for women with no experience of PID (0.84), while Trent et al. [72] reported similar values for adolescents (0.84) and higher values for their parents (0.91). The Institute of Medicine's study reported a utility value of 0.82 by using the HUI-2 tool; infertility was assumed to last for the woman's remaining lifetime [73] . Songer et al. [75] used a scaling method to compare preferences for infertility against a range of chronic conditions as they felt that TTO techniques were not suitable for eliciting the preferences associated with infertility. The authors reported that infertility was viewed as worse than a chronic headache by 48% and as worse than paralysis by 12% of the participants. There were differences in preferences based on experience of previous pregnancies and the number of children respondents had.
Chronic pelvic pain
Utility values for chronic pelvic pain were reported by four of the studies. Kuppermann et al. [74] obtained preference values by using TTO techniques with the patients in their cross-sectional study of women seeking care for noncancerous pelvic problems. The women generated a utility value of 0.83 for their pain on the basis of living for the rest of their lives with their current symptoms. Smith et al. [71] also provided values from a patient perspective; women with experience of PID generated a value of 0.69 for pelvic pain compared with a value of 0.79 provided by women without experience of PID. The description of the health state used by Smith et al. was slightly different to that adopted in [72] . The study by the Institute of Medicine generated an HUI-2 value of 0.60, and the condition was assumed to last for the remainder of the woman's life [73] .
Discussion
This systematic review found 19 published economic evaluations about chlamydia infection and associated sequelae that reported outcomes as cost per QALY. Half of the articles used the same source for HSUVs, but several applied modified values or altered the duration for which they were applied. Half of the economic evaluations mentioned some difficulties associated with valuing the health states for chlamydia. Most studies analyzed the uncertainty around HSUV estimates for the state of infection and its sequelae through a sensitivity analysis, but none discussed in detail the implications associated with the primary research informing their HSUV estimates. There were five primary studies that provided HSUVs for health states relevant to chlamydia infection; all but one used direct methods to value health states. As for many infectious diseases, understanding the impact of chlamydia on HRQOL involves assessing the nature and epidemiology of the sequelae and our ability to link them back to infection. In the majority of the economic evaluations, limitations around our understanding of HRQOL for the health states associated with chlamydia and its sequelae were not fully explored and the ways in which health states had been conceptualized and valued were not discussed in detail. For example, the primary studies demonstrated that health states were valued very differently depending on the characteristics of the research participants (e.g., patients or public), but the economic evaluations reviewed did not discuss the implications associated with the values they adopted. In economic evaluations of diseases in which the primary evidence is limited, balancing the need to adequately reflect the decision problem and disease processes against the availability and quality of data can be problematic [12] . While the economic evaluations have clearly attempted to tackle the complexities involved in understanding the effects of interventions in this area, we believe that it is imperative that such studies fully convey the limitations in our knowledge about the sequelae of chlamydia and about preference-based HRQOL for these conditions, to ensure that decision makers are fully informed and to emphasize the importance of further primary research to inform such economic analyses.
None of the utility values reported in the primary studies we identified could be used without reservation to inform economic evaluations in the United Kingdom. When selecting HSUVs from the literature, it is important to consider both the methods used to generate the values and their relevance to the population under consideration [4] . In this instance, the methods used in the primary studies would need to be considered against the "reference case" methods for estimating cost-effectiveness set out by NICE, which recommends that HRQOL be measured directly by patients or their carers and that these measurements be valued by a representative sample of the general population by using a choice-based method [15] . The study by the Institute of Medicine relied on expert views to measure HRQOL, which is generally seen as less preferable than measuring patient experiences of health states directly [4] . The remaining studies used scenarios to value HRQOL rather than direct patient measurement. There [5] . For chlamydia, it is difficult to measure patient-reported HRQOL directly because sequelae can happen a long time after the initial infection and cannot be etiologically linked. This means that most primary studies to date have used direct valuation methods using descriptions of health states. Direct valuation methods, however, are seen as less robust, because there is no clear link to patient-reported HRQOL [4] . For conditions in which it is difficult to measure preferences indirectly, there is a need for further discussion about the most effective ways to elicit utility values to inform economic evaluations [76] . There is a growing body of research examining the impact of stigma on HRQOL in relation to STIs and other conditions [77] [78] [79] [80] , and there have been attempts to include the effects of stigma in the valuation of health states [81] , but further exploration of such issues is needed.
Infectious diseases such as chlamydia involve combinations of short-and long-term health states. There is evidence that preferences for health states may be partly affected by their duration, and there is ongoing debate about how we overcome such problems [44, 82] . There is also discussion about how we incorporate time preference within valuations of health states, which is pertinent to research involving chlamydia and other diseases, in which complications may occur or be detected many years after the initial infection [46, 83] . The primary studies we identified demonstrated that different values were obtained for different groups of participants, which has implications for broader methodological discussions about whose preferences should be used to value health states [47, 48] . This issue is particularly important for STIs because of the asymmetry between men and women in the burden associated with the complications of disease, even though both sexes acquire and transmit the infection itself.
We identified two previous systematic reviews focusing on outcomes for economic evaluations relating to chlamydia infection. Roberts et al. [17] reviewed economic evaluation and modeling studies in this area published up to 2004. Approximately half of the studies reviewed used "cost per case detected" as the main outcome. This is not an appropriate base for policy decisions because these are only surrogate end points and do not determine the success of the intervention for chlamydia. The current review shows that the use of cost per QALY has increased markedly, possibly as a reflection of the impact of recommendations made by NICE, the Pharmaceutical Benefits Advisory Committee in Australia. and other decision-making bodies [15, 16, 84] . A second review described alternative approaches to measure and value the quality of life associated with the sequelae of chlamydia and considered studies up to the end of 2011 [85] . The authors concluded that it was not possible to reach firm conclusions about the most appropriate techniques for measuring HRQOL and valuing outcomes for chlamydia. The current review examines how HSUVs have been used within economic evaluations, and it critically examines the primary data available to inform cost-effectiveness studies, based on a wide range of search terms.
Strengths and Limitations
The main strength of this study is that it provides a comprehensive overview of economic evaluations about chlamydia infection that have reported their results in terms of cost per QALY. Another strength is the critical appraisal of HSUVs that have been used in existing economic evaluations alongside a consideration of the wider primary evidence on HSUVs and associated methodological issues. There are also weaknesses associated with this review. Some studies were not explicit in stating that the condition under study was associated with chlamydia. Hence, reviewers had to use their judgment to determine which studies should be included and might have incorrectly included or excluded relevant publications. Another weakness relates to the different methods that have been used to value HRQOL, which makes it difficult to make comparisons between studies and reach conclusions on the differences between them.
Conclusions
There is limited information about HSUVs associated with chlamydia infection and its complications, which has implications for the robustness of economic evaluations in this area. Future economic evaluations need to be firmly rooted in our understanding of the natural history of the disease and its sequelae and fully discuss any limitations associated with the underlying evidence, to ensure that decision makers are as informed as possible and to inform future research agendas. To be in line with generic NICE guidelines for economic evaluations, future research is needed to understand preferences for health states associated with chlamydia. We would argue that such research needs to fully engage with wider methodological debates about how we measure and value health states. The valuation of health states for chlamydia and other infectious diseases can be particularly challenging because it may not be possible to use the methods that are generally viewed to be the most robust. For example, complications may occur many years after the initial infection and cannot be etiologically linked, which means that direct measurement of patient-reported HRQOL and the application of indirect valuation methods are not possible. Thus, there needs to be further exploration of the most appropriate methods of value elicitation to use in different settings, to ensure the best match of methods to the aims of the research [76] . In addition, further exploration is required around methods for valuing and combining preferences for health states of varying duration and occurring over different time horizons. Issues relating to the measurement and valuation of the effects of stigma, and debates about whose preferences count, also need to be examined in greater depth. Unless we adequately tackle the challenges associated with measuring and valuing HRQOL for chlamydia and other infectious diseases, evaluating the cost-effectiveness of interventions in this area will remain problematic.
